MRs at 12 and 24 months in cohorts 1 and 2
| . | Cohort 1 . | Cohort 2 . | Total . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | 95% CI (%) . | No. . | % . | 95% CI (%) . | No. . | % . | 95% CI (%) . | |
| 12 months | |||||||||
| Withdrawn | 7 | 6.6 | 2.1-12 | 8 | 7.6 | 2.8-13 | 15 | 7.1 | 3.6-11 |
| BCR-ABL1 >1.0% IS | 6 | 5.7 | 1.5-11 | 6 | 5.7 | 1.5-11 | 12 | 5.7 | 2.6-8.8 |
| BCR-ABL1 ≤1.0% IS | 92 | 88 | 82-94 | 91 | 87 | 81-93 | 183 | 87 | 82-92 |
| Confirmed MMR* | 69 | 66 | 57-75 | 65 | 62 | 53-71 | 134 | 64 | 56-72 |
| BCR-ABL1 ≤0.0032% IS | 16 | 15 | 8-22 | 23 | 22 | 14-30 | 39 | 19 | 14-24 |
| BCR-ABL1 ≤0.001% IS | 13 | 12 | 5.8-18 | 18 | 17 | 10-24 | 31 | 15 | 10-20 |
| Confirmed CMR* | 11 | 10 | 4.3-16 | 13 | 12 | 5.8-18 | 24 | 11 | 6.8-15 |
| 24 months | |||||||||
| Withdrawn | 16 | 15 | 8.2-22 | 16 | 15 | 8.2-22 | 32 | 15 | 10-20 |
| BCR-ABL1 >1.0% IS | 0 | 0 | 2 | 1.9 | 0-4.7 | 2 | 1.0 | 0-2.4 | |
| BCR-ABL1 ≤1.0% IS | 89 | 85 | 78-92 | 87 | 83 | 76-90 | 176 | 84 | 79-89 |
| Confirmed MMR* | 80 | 76 | 68-84 | 73 | 70 | 61-79 | 153 | 73 | 67-79 |
| BCR-ABL1 ≤0.0032% IS | 36 | 34 | 25-43 | 35 | 33 | 24-42 | 71 | 34 | 28-40 |
| BCR-ABL1 ≤0.001% IS | 32 | 30 | 21-39 | 34 | 32 | 23-41 | 66 | 31 | 25-37 |
| Confirmed CMR* | 23 | 22 | 14-30 | 29 | 28 | 19-37 | 52 | 25 | 19-31 |
| . | Cohort 1 . | Cohort 2 . | Total . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | 95% CI (%) . | No. . | % . | 95% CI (%) . | No. . | % . | 95% CI (%) . | |
| 12 months | |||||||||
| Withdrawn | 7 | 6.6 | 2.1-12 | 8 | 7.6 | 2.8-13 | 15 | 7.1 | 3.6-11 |
| BCR-ABL1 >1.0% IS | 6 | 5.7 | 1.5-11 | 6 | 5.7 | 1.5-11 | 12 | 5.7 | 2.6-8.8 |
| BCR-ABL1 ≤1.0% IS | 92 | 88 | 82-94 | 91 | 87 | 81-93 | 183 | 87 | 82-92 |
| Confirmed MMR* | 69 | 66 | 57-75 | 65 | 62 | 53-71 | 134 | 64 | 56-72 |
| BCR-ABL1 ≤0.0032% IS | 16 | 15 | 8-22 | 23 | 22 | 14-30 | 39 | 19 | 14-24 |
| BCR-ABL1 ≤0.001% IS | 13 | 12 | 5.8-18 | 18 | 17 | 10-24 | 31 | 15 | 10-20 |
| Confirmed CMR* | 11 | 10 | 4.3-16 | 13 | 12 | 5.8-18 | 24 | 11 | 6.8-15 |
| 24 months | |||||||||
| Withdrawn | 16 | 15 | 8.2-22 | 16 | 15 | 8.2-22 | 32 | 15 | 10-20 |
| BCR-ABL1 >1.0% IS | 0 | 0 | 2 | 1.9 | 0-4.7 | 2 | 1.0 | 0-2.4 | |
| BCR-ABL1 ≤1.0% IS | 89 | 85 | 78-92 | 87 | 83 | 76-90 | 176 | 84 | 79-89 |
| Confirmed MMR* | 80 | 76 | 68-84 | 73 | 70 | 61-79 | 153 | 73 | 67-79 |
| BCR-ABL1 ≤0.0032% IS | 36 | 34 | 25-43 | 35 | 33 | 24-42 | 71 | 34 | 28-40 |
| BCR-ABL1 ≤0.001% IS | 32 | 30 | 21-39 | 34 | 32 | 23-41 | 66 | 31 | 25-37 |
| Confirmed CMR* | 23 | 22 | 14-30 | 29 | 28 | 19-37 | 52 | 25 | 19-31 |
Patients who achieved deeper MRs are not excluded from the calculation of less stringent MRs. For instance, 134 patients achieved confirmed MMR at 12 months in total, of which 39 had achieved MR4.5 at 12 months. Patients who withdrew prior to the specified time point were included as having failed to achieve the relevant response.
Several responses at both the CMR and MMR level at 24 months could not be confirmed because of missing values at the subsequent time point.